SE0000718D0 - New use - Google Patents

New use

Info

Publication number
SE0000718D0
SE0000718D0 SE0000718A SE0000718A SE0000718D0 SE 0000718 D0 SE0000718 D0 SE 0000718D0 SE 0000718 A SE0000718 A SE 0000718A SE 0000718 A SE0000718 A SE 0000718A SE 0000718 D0 SE0000718 D0 SE 0000718D0
Authority
SE
Sweden
Prior art keywords
target polypeptide
glucose
prevention
identifying
treatment
Prior art date
Application number
SE0000718A
Other languages
Swedish (sv)
Inventor
Marguerite Luthman
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE0000718A priority Critical patent/SE0000718D0/en
Publication of SE0000718D0 publication Critical patent/SE0000718D0/en
Priority to US09/797,227 priority patent/US20010019832A1/en
Priority to JP2001563106A priority patent/JP2003525431A/en
Priority to CA002399889A priority patent/CA2399889A1/en
Priority to EP01912628A priority patent/EP1259232A1/en
Priority to PCT/SE2001/000450 priority patent/WO2001064209A1/en
Priority to AU2001241316A priority patent/AU2001241316A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method for identifying an agent useful for the treatment or prevention of a medical condition related to reduced cellular uptake of glucose, said method comprising the steps of: (i) identifying a target polypeptide interacting with the compound U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene); (ii) contacting a candidate agent with the said target polypeptide; and (iii) determining whether said candidate agent modulates the biological activities of the said target polypeptide, such modulation being indicative for an agent useful for the treatment or prevention of a medical condition related to reduced cellular uptake of glucose.
SE0000718A 2000-03-03 2000-03-03 New use SE0000718D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0000718A SE0000718D0 (en) 2000-03-03 2000-03-03 New use
US09/797,227 US20010019832A1 (en) 2000-03-03 2001-03-01 Methods for identification using U0126
JP2001563106A JP2003525431A (en) 2000-03-03 2001-03-02 Method for identifying a medicament for treating NIDDM-diabetes by interacting with compound U0126
CA002399889A CA2399889A1 (en) 2000-03-03 2001-03-02 Method for identifying an agent for treatment of niddm diabetes by interaction with compound u0126
EP01912628A EP1259232A1 (en) 2000-03-03 2001-03-02 Method for identifying an agent for treatment of niddmdiabetes by interaction with compound u0126
PCT/SE2001/000450 WO2001064209A1 (en) 2000-03-03 2001-03-02 Method for identifying an agent for treatment of niddmdiabetes by interaction with compound u0126
AU2001241316A AU2001241316A1 (en) 2000-03-03 2001-03-02 Method for identifying an agent for treatment of niddmdiabetes by interaction with compound u0126

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000718A SE0000718D0 (en) 2000-03-03 2000-03-03 New use

Publications (1)

Publication Number Publication Date
SE0000718D0 true SE0000718D0 (en) 2000-03-03

Family

ID=20278690

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000718A SE0000718D0 (en) 2000-03-03 2000-03-03 New use

Country Status (6)

Country Link
EP (1) EP1259232A1 (en)
JP (1) JP2003525431A (en)
AU (1) AU2001241316A1 (en)
CA (1) CA2399889A1 (en)
SE (1) SE0000718D0 (en)
WO (1) WO2001064209A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE212552T1 (en) * 1998-04-17 2002-02-15 Tufts College MAP KINASE INHIBITORS FOR THE TREATMENT OF TNF-ALPHA INDUCED LIPOLYSIS CAUSED DISEASES

Also Published As

Publication number Publication date
AU2001241316A1 (en) 2001-09-12
EP1259232A1 (en) 2002-11-27
WO2001064209A1 (en) 2001-09-07
CA2399889A1 (en) 2001-09-07
JP2003525431A (en) 2003-08-26

Similar Documents

Publication Publication Date Title
BR9808348A (en) Medicinal food for diabetics
NO20011351L (en) Method of treating diabetes using an AP2 inhibitor and combination thereof
EA200200105A1 (en) Compounds modulating PPARγ activity;
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
CY1109062T1 (en) METHODS OF DETERMINING AND ANTI-VASCULAR Suspension
ATE324106T1 (en) COMPOSITIONS AND METHODS FOR REGULATING SERUM CHOLESTEROL
TW200505829A (en) Protease inhibitors for coronaviruses and sars-cov and the use thereof
BR9815469A (en) Protease inhibitors
BR9913190A (en) Modulation of multiple lineage protein kinase
BR9813996A (en) 2-arylbenzo [b] thiophenes useful for the treatment of estrogen deprivation syndrome
ATE383870T1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES WITH GPR49
DE60231969D1 (en) sPLA2-INHIBITORS FOR THE TREATMENT OF ARTERIOSCLEROSIS
PT1147420E (en) URINARY TRYSPIN INHIBITOR FOR AIDS DIAGNOSIS
SE0000718D0 (en) New use
GB9930768D0 (en) Composition
WO2004109290A3 (en) Methods for identifying modulators of kinesin activity
DE69905489D1 (en) PROTEIN C FOR THE TREATMENT OF SICKLE LEMENIA AND THALASSEMIA
DE69925301D1 (en) COMPOSITION OF RILUZOLE AND ALPHA-TOCOPHEROL
AU2003211660A1 (en) Sumo inhibitors
WO2005075632A3 (en) Treatment of neurodegenerative diseases by the use of atp7a-modulators
ATE362545T1 (en) SCREENING PROCEDURE FOR SUBSTANCES FOR THE TREATMENT OF DIABETES
CY1110278T1 (en) A METHOD OF DIAGNOSTING FACTORS TO Cure OBESITY
WO2002024204A3 (en) Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter
DK1366033T3 (en) Chemical compounds
BR9807920A (en) Processes for treating dementia in a subject and for preventing dementia